Company news
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) news
Rocket Pharmaceuticals, Inc. news releases on 6ix. Latest, Jun 29, 2020: Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy…
Press releases — page 4
Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis
June 28, 2020
Rocket Pharmaceuticals Announces Private Exchange Transaction Regarding Its Outstanding Convertible Senior Notes due 2021
June 7, 2020
Rocket Pharmaceuticals Announces Participation at the Jefferies Virtual Healthcare Conference
May 25, 2020
Rocket Pharmaceuticals Presents Positive Updates on FA and LAD-I Gene Therapy Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
May 11, 2020
Rocket Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Progress
May 5, 2020
Rocket Pharmaceuticals Announces Participation at the BofA Securities 2020 Health Care Conference
May 4, 2020
Rocket Pharmaceuticals Appoints Elisabeth Bjӧrk, M.D., Ph.D. to Board of Directors
April 21, 2020
Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic
April 1, 2020
Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
April 1, 2020
Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease
March 18, 2020
Rocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights
March 4, 2020
Rocket Pharmaceuticals Announces Publication of Manuscript Evaluating Mosaicism in Fanconi Anemia
February 23, 2020
Rocket Pharmaceuticals Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes due 2021
February 10, 2020
Rocket Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Awareness
February 5, 2020
Rocket Pharmaceuticals Announces Participation at the 38th Annual J.P. Morgan Healthcare Conference
January 5, 2020
Rocket Pharmaceuticals Receives the European Medicines Agency PRIME Eligibility for RP-L102 Gene Therapy for Fanconi Anemia
December 15, 2019
Rocket Pharmaceuticals Announces Closing of Public Offering
December 12, 2019
Rocket Pharmaceuticals Prices Public Offering of Common Stock
December 9, 2019
Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I
December 8, 2019
Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting
December 7, 2019
Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 “Process B” for Fanconi Anemia
December 5, 2019
Rocket Pharmaceuticals to Host Breakout Session at 61st American Society of Hematology Annual Meeting
December 4, 2019
Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
November 6, 2019
Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 “Process B” for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting
November 5, 2019
Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit
November 4, 2019
Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 “Process A” for Fanconi Anemia
October 23, 2019
Rocket Pharmaceuticals Announces Clearance of IND for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
October 21, 2019
Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress
October 14, 2019
Rocket Pharmaceuticals Announces Participation at the Chardan 3rd Annual Genetic Medicines Conference
September 30, 2019
Rocket Pharmaceuticals Announces IMPD Clearance of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
September 22, 2019
Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine
September 9, 2019